WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=150973&from=3 C ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Far ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

公司动态 - Iovance Biotherapeutics因涉嫌在2024年5月9日至2025年5月8日期间误导投资者被提起集体诉讼 [1] - 公司被指控未披露以下信息：新授权治疗中心(ATCs)启动Amtagvi治疗的时间延长、销售团队和ATCs在患者识别和选择方面效率低下导致患者流失增加、上述问题导致成本上升和收入下降 [2] - 2025年5月8日公布的第一季度财报显示产品总收入为4930万美元，较上一季度的7370万美元大幅下降 [3] - 公司下调2025财年总收入指引，从4.5-4.75亿美元降至2.5-3亿美元，降幅超过40% [3] - 股价在财报发布次日下跌1.42美元(44.8%)，收于1.75美元 [3] 产品与市场 - Iovance Biotherapeutics是一家商业化阶段的生物制药公司，专注于开发治疗转移性黑色素瘤和其他实体瘤癌症的细胞疗法 [1] - 公司表示下调收入指引是基于Amtagvi近期上市表现和ATCs增长轨迹及治疗时间表的实际经验 [3] 法律进展 - 针对Iovance Biotherapeutics的集体诉讼正在进行中，股东可在2025年7月14日前申请成为首席原告 [4] - Robbins LLP律师事务所自2002年以来专注于股东权利诉讼，帮助股东挽回损失并追究公司高管责任 [5]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Iovance and certa ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts cla ...

LOS ANGELES, June 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws.Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before July 14, 2025.CASE DETAILS: The complaint alleges that the Company made false and misleading statements to the market ...

文章核心观点 - Iovance Biotherapeutics公司公布Amtagvi治疗晚期黑色素瘤的5年随访结果，显示出长期益处和良好安全性，为该疾病治疗带来新标准 [2][4][6] 公司动态 - Iovance Biotherapeutics宣布《临床肿瘤学杂志》发表C - 144 - 01临床试验最终分析，结果在2025年美国临床肿瘤学会年会上同步展示 [2] - 公司正在进行TILVANCE - 301三期试验，以确认Amtagvi在一线晚期黑色素瘤中的临床益处 [6] 试验情况 C - 144 - 01临床试验 - 这是一项全球多中心二期研究，入组曾接受至少一种全身治疗的转移性黑色素瘤患者，疗效基于客观缓解率和缓解持续时间评估 [7] - 最终五年分析纳入153名来自2和4队列的患者 [3] 试验结果 - 单次Amtagvi治疗在预处理患者中显示长期益处，客观缓解率31.4%，中位缓解时间1.4个月，中位缓解持续时间36.5个月，近三分之一缓解者五年评估时仍有持续缓解，中位总生存期13.9个月，五年生存率19.7% [4] - 安全性与非清髓性淋巴细胞清除和白细胞介素 - 2给药一致，不良事件发生率在输注后两周内迅速下降，无新的或迟发性治疗相关不良事件 [5] 药物相关 Amtagvi药物信息 - 用于治疗无法手术切除或已转移的黑色素瘤成人患者，是首个用于实体肿瘤癌症的一次性T细胞疗法 [6][9] - 其获批基于C - 144 - 01临床试验的总体缓解率和缓解持续时间，持续批准可能取决于正在进行的研究结果 [6][10] 用药注意事项 - 用药前后可能需住院，用药前需告知医生医疗状况和用药情况 [11][12] - 用药后3至24小时可能给予最多6剂IL - 2，医生可因严重副作用随时停药 [11] - 常见副作用包括寒战、发热、白细胞计数低等 [14] 公司介绍 - Iovance Biotherapeutics旨在成为肿瘤浸润淋巴细胞疗法全球领导者，利用人体免疫系统治疗癌症，其Amtagvi是首个获FDA批准用于实体肿瘤的T细胞疗法 [16] 联系方式 - 媒体联系邮箱PR@iovance.com，电话650 - 260 - 7120分机150 [20] - 投资者联系邮箱IR@iovance.com，电话650 - 260 - 7120分机150 [20]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...